Posted by Michael Wonder on 26 Jun 2024
ExCellThera announces EMA’s acceptance under accelerated assessment of market authorisation application for UM171 cell therapy for patients with haematological malignancies who lack a readily available suitable donor
25 June 2024 - ExCellThera announced today that the market authorisation application for UM171 cell therapy (INN-dorocubicel) has been accepted under an accelerated assessment procedure by the EMA for adult patients with haematological malignancies requiring a stem cell transplant who lack a readily available suitable donor.
The EMA’s CHMP granted UM171 cell therapy accelerated assessment as it was deemed of major interest from a public health point of view.
